Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo
Trial details
- Registry ID
- NCT04221230
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as BTRX 335140; BTRX-335140; CYM-53093; Navacaprant
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs PlaceboNCT04221230 | NMRA | Phase 2 | Completed | 2022-04-08Actual |
| Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive DisorderNCT06058039 | NMRA | Phase 3 | Completed | 2026-05-04Actual |
| Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderNCT06029426 | NMRA | Phase 3 | Completed | 2024-12-03Actual |
| Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderNCT06058013 | NMRA | Phase 3 | Completed | 2026-05-06Actual |
| Study to Assess the Safety and Effectiveness of NMRA-335140-501NCT06029439 | NMRA | Phase 3 | Terminated | 2026-08-17Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |